SGAM
ALNY icon

Smith Group Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Smith Group Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,750
Closed -$647K – 180
2024
Q4 		$647K Sell
2,750
-50
-2% -$13.2K 0.05% 116
2024
Q3 		$770K Buy
+2,800
New +$729K 0.06% 74
2013
Q3 		– Sell
-69,031
Closed -$2.14M – 413
2013
Q2 		$2.14M Buy
+69,031
New +$1.84M 0.09% 161

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Smith Group Asset Management's ALNY Position: Q1 2025 in Review

Smith Group Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 2,750 shares — an estimated $647K sold.

Smith Group Asset Management first reported a position in ALNY in Q2 2013 and held it in 3 quarters. The position peaked at $2.14M in Q2 2013. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Smith Group Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Smith Group Asset Management sold 2,750 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $647K.
  • Smith Group Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Smith Group Asset Management's Alnylam Pharmaceuticals position peaked at $2.14M in Q2 2013.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Smith Group Asset Management's 13F filing for Q1 2025, filed 28 Apr 2025.